Clarity Pharmaceuticals Ltd has released a press release.
Diagnostic prostate cancer trial reaches recruitment target
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Positive topline results from SAR-bisPSMA diagnostic trial
- Managing Directors Presentation to AGM
- Chairmans Address to Shareholders
- IND approval from the FDA for theranostic SAR-Bombesin trial
- Clarity Presentation -Bell Potter Healthcare Conference 2022
Later from Clarity Pharmaceuticals
- PROPELLER Trial Results
- 50% recruitment milestone for NET diagnostic Phase II trial
- Clarity Corporate Presentation
- Clarity Receives $6.7 million R&D Tax Incentive Refund
- Theranostic prostate cancer trial advances to cohort 2
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals